Medpace CEO August Troendle sells shares on two days

Both transactions were made under a limit order during an open window period, with weighted-average prices of $623.2900 and $628.1100 per share.

Rhea-AI Filing Summary

Medpace Holdings, Inc. (MEDP) President & CEO, director and ten percent owner August J. Troendle sold 21,883 common shares on September 21, 2026, at a weighted average price of $623.2900 per share, and 49,018 shares on September 22, 2026, at a weighted average price of $628.1100 per share. The reported price ranges were $620.00 to $625.91 and $620.00 to $632.815, respectively. Both sales were made pursuant to a limit order placed during an open window period, and no Rule 10b5-1 plan is reported. Separately, Medpace Investors, LLC held 4,733,019 shares as of September 21, 2026. Troendle is the LLC’s sole manager and controlling unit holder, has sole voting and investment control, and disclaims beneficial ownership except to the extent of his pecuniary interest.

Insider Trade Summary

Net Seller: 70,901 shares

Net Sell 3 txns

Insider Troendle August J.

Role President & CEO

Sold 70,901 shs ($44.43M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F3	49,018	$628.11	$30.79M
Sale	Common Stock F1, F2	21,883	$623.29	$13.64M
holding	Common Stock F4	--	--	--

Holdings After Transaction: Common Stock — 433,372 shares (Direct); Common Stock — 4,733,019 shares (Indirect, By Medpace Investors, LLC)

Footnotes (4)

1. F1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.
2. F2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $625.91. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
3. F3. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $632.815. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
4. F4. The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Key Figures

Shares sold: 21,883 shares Weighted average sale price: $623.2900 per share Reported sale price range: $620.00 to $625.91 per share +4 more

7 metrics

Shares sold 21,883 shares September 21, 2026

Weighted average sale price $623.2900 per share September 21, 2026

Reported sale price range $620.00 to $625.91 per share Shares sold September 21, 2026

Shares sold 49,018 shares September 22, 2026

Weighted average sale price $628.1100 per share September 22, 2026

Reported sale price range $620.00 to $632.815 per share Shares sold September 22, 2026

Shares held by Medpace Investors, LLC 4,733,019 shares September 21, 2026

Key Terms

weighted average price, limit order, open window period, pecuniary interest

4 terms

weighted average price financial

"The reported price is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

limit order financial

"effected pursuant to a limit order placed by the Reporting Person"

A limit order is an instruction to buy or sell a stock only at a specific price or better, giving you control over the exact price you pay or receive. It matters to investors because it acts like a price guard—similar to setting a maximum you’ll pay for an item at a store—so you avoid unexpected prices, though the trade may not happen if the market never reaches your limit.

open window period regulatory

"placed by the Reporting Person during an open window period"

pecuniary interest financial

"except to the extent of his pecuniary interest therein"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MEDP shares did its CEO sell, and at what prices?

August J. Troendle sold 21,883 shares on September 21, 2026, at a weighted average price of $623.2900 per share, and 49,018 shares on September 22, 2026, at a weighted average price of $628.1100 per share. Reported price ranges were $620.00 to $625.91 and $620.00 to $632.815, respectively.

Were MEDP CEO August J. Troendle’s sales under a Rule 10b5-1 plan?

No Rule 10b5-1 plan is reported for the sales. They were effected pursuant to a limit order placed by Troendle during an open window period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/23/2026 - 04:06 PM Accepted by SEC EDGAR 09/23/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Troendle August J.

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OHIO 45227

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/21/2026		S(1)		21,883	D	$623.29(2)	482,390	D
Common Stock	09/22/2026		S(1)		49,018	D	$628.11(3)	433,372	D
Common Stock								4,733,019	I	By Medpace Investors, LLC(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.

2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $625.91. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

3. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $632.815. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

4. The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for August J. Troendle	09/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)